A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Recruiting now · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumors, Malignant Neoplasm

In brief

Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.

Key facts

Study ID

NCT06818643

Run by

Merck Sharp & Dohme LLC

People needed

270

Starts

2025-03-25

Expected to finish

2031-03-25

Last updated by the study team

2026-07-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Has a confirmed advanced (unresectable and/or metastatic) solid tumor and has received or been intolerant to all available treatments
• If human immunodeficiency virus (HIV) positive, has well controlled HIV on antiretroviral therapy (ART)
• If hepatitis B surface antigen (HBsAg) positive, must have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
• If hepatitis C virus (HCV) infected, must have undetectable HCV viral load

You may not qualify if…

• Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
• Has uncontrolled significant cardiovascular disease or cerebrovascular disease
• Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
• Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage
• Is HIV-positive and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
• Known additional malignancy that is progressing or has required active treatment within the past 2 years
• Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
• Active infection requiring systemic therapy, with exceptions
• History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
• Has HBV or HCV infection

Where it is running

• The University of Alabama at Birmingham ( Site 1005) — Birmingham, Alabama, United States (enrolling)
• University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1003) — Miami, Florida, United States (enrolling)
• John Theurer Cancer Center at Hackensack University Medical Center ( Site 1009) — Hackensack, New Jersey, United States (enrolling)
• NEXT Oncology ( Site 1010) — Austin, Texas, United States (enrolling)
• NEXT Oncology ( Site 1011) — Houston, Texas, United States (enrolling)
• NEXT Oncology ( Site 1012) — Irving, Texas, United States (enrolling)
• Virginia Commonwealth University ( Site 1008) — Richmond, Virginia, United States (enrolling)
• Centro de Estudios Clínicos SAGA ( Site 0033) — Santiago, Region M. de Santiago, Chile (enrolling)
• FALP ( Site 0031) — Santiago, Region M. de Santiago, Chile (enrolling)
• Pontificia Universidad Catolica de Chile ( Site 0032) — Santiago, Region M. de Santiago, Chile (enrolling)
• Bradford Hill Centro de Investigaciones Clinicas ( Site 0030) — Santiago, Region M. de Santiago, Chile (enrolling)
• Peking University First Hospital ( Site 0180) — Beijing, Beijing Municipality, China (enrolling)
• Chongqing Cancer Hospital ( Site 0186) — Chongqing, Chongqing Municipality, China (enrolling)
• Hunan Cancer Hospital ( Site 0181) — Changsha, Hunan, China (enrolling)
• The First Hospital of Jilin University ( Site 0185) — Changchun, Jilin, China (enrolling)
• West China Hospital Sichuan University ( Site 0187) — Chengdu, Sichuan, China (enrolling)
• Institut Paoli Calmettes ( Site 0053) — Marseille, Bouches-du-Rhone, France (enrolling)
• Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 0054) — Rennes, Ille-et-Vilaine, France (enrolling)
• Centre Oscar Lambret ( Site 0051) — Lille, Nord, France (enrolling)
• Gustave Roussy ( Site 0050) — Villejuif, Val-de-Marne, France (enrolling)
• Rambam Health Care Campus ( Site 0082) — Haifa, Israel (enrolling)
• Rabin Medical Center ( Site 0081) — Petah Tikva, Israel (enrolling)
• Sheba Medical Center ( Site 0080) — Ramat Gan, Israel (enrolling)
• National Cancer Center Hospital East ( Site 0190) — Kashiwa, Chiba, Japan (enrolling)
• Cancer Institute Hospital of JFCR ( Site 0192) — Koto, Tokyo, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.